NS Pharma, Inc. announced today the first patient enrollment in a Phase 2 clinical study of NS-018  an investigational treatment for myelofibrosis a rare and incurable blood cancer.

The Phase 2b study is an open-label, multicenter, randomized, controlled, 2-arm study to assess the efficacy and safety of orally administered NS-018 versus best available therapy in subjects with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis with severe thrombocytopenia (Platelet Count <50,000/μL).

ClinicalTrials.gov identifier: NCT04854096
(https://clinicaltrials.gov/ct2/show/NCT04854096)

Source:prnewswire.com